To ensure that GARDP focuses its scientific portfolio towards meeting priority needs, its R&D prioritization process begins with the requirement that any programme meets at least two out of three key criteria:

  1. target priority pathogens
  2. address priority diseases and syndromes
  3. help underserved priority patient populations.

Combining these three fields provides a decisional tool to identify priority needs. Attention will be brought to ensuring that no efforts undertaken by others are duplicated. This prioritization process capitalizes on WHO’s prior and ongoing work on: prioritization and review of pathogens through the Priority Pathogens List that clearly shows the need to address certain gram-negative bacteria priority infectious disease syndromes review that points to major evidence-base gaps particularly on paediatric populations, and a qualitative and quantitative review of the antibiotic R&D pipeline. Other published literature and reports, as well as stakeholder consultations, form part of this prioritization process.

Potential programmes are then subjected to the following criteria before selection as part of the GARDP portfolio: global health need with clear relevance for developing countries gap in R&D left by existing actors potential for short- to medium-term fruition R&D opportunity and potential to partner effectively, and potential or ability to test and/or apply access and stewardship strategies.

 

*GARDP will promote and stimulate diagnostic actors and funders to engage in relevant R&D for diagnostics, especially where this will contribute to improved use of drugs in GARDP programmes.